Summary: This will be Endpoints’ 2021 look at 11 of the most important up-and-coming private biotechs in the business, independently selected by company founder and editor John Carroll.

Summary: This webinar summarizes the current bioanalytical landscape and its challenges, and discusses strategies to overcome them.

Summary: In this webinar, key leaders in the field talk about where this is headed, and how it may more broadly affect everyone doing antibody research and development.

Summary: Plasmid DNA is a critical raw material for cell and gene therapies. Discover the importance of having an integrated partner like Catalent Cell & Gene, and how we can keep your development and manufacturing on track and on schedule.

Summary: This webinar offers tips for incorporating elements of the successful COVID-19 vaccine rollout into future vaccine programs.

Summary: Due to advances in technology and increased development of parenteral drugs, one of the fastest growing choices for drug delivery in the pharmaceutical industry is the prefilled syringe (PFS).

Summary: Catalent Biologics’ drug substance biomanufacturing services provide flexibility and scale to support your growth from clinical to commercial, with options to utilize single-use or stainless-steel bioreactors in a rigorous CGMP environment.

Summary: The Catalent team has broad expertise in developing customized plasmid DNA manufacturing solutions, from plasmid engineering to large-scale GMP plasmid production.

Summary: This podcast focuses on the specialized needs of manufacturing cell therapies at scale and how Custom Manufacturing Organizations are stepping in to drive process efficiencies and standardization.

Summary: During this talk, we share the latest data leveraging GPEx Lightning to generate highly stable, highly productive cell pools and discuss how the GPEx suite of technologies can be tailored to the specific needs of each individual program on its path to clinical trials.